Mortality did not decrease, compared with placebo, in patients with chronic obstructive pulmonary disease (COPD) and cardiovascular disease risk who took the inhaled corticosteroid fluticasone furoate ...

Fluticasone furoate/vilanterol (FF/VI) improved FEV1 but did not improve morning peak expiratory flow in pediatric patients with uncontrolled asthma. Among pediatric patients with uncontrolled asthma, ...

HealthDay News — A combination of fluticasone furoate and vilanterol reduces the rate of moderate or severe exacerbations among patients with chronic obstructive pulmonary disease (COPD), according to ...

To assess the safety and efficacy of fluticasone furoate nasal spray (FFNS) compared with placebo for symptomatic relief of uncomplicated ARS. A statistically significant reduction was seen in the ...

Trelegy Ellipta combines fluticasone furoate, an inhaled corticosteroid with umeclidinium, an anticholinergic and vilanterol, a long-acting β2-adrenergic agonist. The Food and Drug Administration (FDA ...

Sandoz Group Ltd ($SDZXF) announced an update on their ongoing clinical study. Study Overview: Sandoz Group Ltd is conducting a clinical study ...

Which therapy more effectively reduces severe COPD exacerbations: once-daily FF/UMEC/VI or twice-daily ICS/LABA? Treatment with once-daily single-inhaler fluticasone ...

LONDON, Aug. 20, 2014 /PRNewswire/ -- GlaxoSmithKline plc today announced that the FDA has approved Arnuity™ Ellipta ® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS ...

Please provide your email address to receive an email when new articles are posted on . Patients with chronic obstructive pulmonary disease treated with a combination of fluticasone furoate and ...

GlaxoSmithKline plc today announced that the Food and Drug Administration has approved Arnuity™ Ellipta® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for ...